Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Tao Li(Army Medical University), Jiannan Yao(Beijing Chaoyang Emergency Medical Center), Haoning Lan(Capital Medical University), Yang Ge(Merck & Co., Inc., Rahway, NJ, USA (United States)), Huiyun Zhang(First Hospital of Lanzhou University), Guangyu An(Capital Medical University), Yaoqi Xu(Capital Medical University)
Cited by 12
Related Papers
COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis
|Journal of Medical Virology|2020|1.6k
Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming
|Advanced Science|2024|76
MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8
|Oncotarget|2016|55
Loss of Bright/ARID3a Function Promotes Developmental Plasticity
|Stem Cells|2010|51